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Abstract
Background: Monoclonal free light chains (FLCs) frequently cause rapidly progressive renal failure
in patients with multiple myeloma. Immunoassays which provide quantitative measurement of FLCs
in serum, have now been adopted into screening algorithms for multiple myeloma and other
lymphoproliferative disorders. The assays indicate monoclonal FLC production by the presence of
an abnormal κ to λ FLC ratio (reference range 0.26–1.65). Previous work, however, has
demonstrated that in patients with renal failure the FLC ratio can be increased above normal with
no other evidence of monoclonal proteins suggesting that in this population the range should be
extended (reference range 0.37–3.1). This study evaluated the diagnostic sensitivity and specificity
of the immunoassays in patients with severe renal failure.
Methods: Sera from 142 patients with new dialysis-dependent renal failure were assessed by
serum protein electrophoresis (SPE), FLC immunoassays and immunofixation electrophoresis. The
sensitivity and specificity of the FLC ratio's published reference range was compared with the
modified renal reference range for identifying patients with multiple myeloma; by receiver
operating characteristic curve analysis.
Results: Forty one patients had a clinical diagnosis of multiple myeloma; all of these patients had
abnormal serum FLC ratios. The modified FLC ratio range increased the specificity of the assays
(from 93% to 99%), with no loss of sensitivity. Monoclonal FLCs were identified in the urine from
23 of 24 patients assessed.
Conclusion: Measurement of serum FLC concentrations and calculation of the serum κ/λ ratio is
a convenient, sensitive and specific method for identifying monoclonal FLC production in patients
with multiple myeloma and acute renal failure. Rapid diagnosis in these patients will allow early
initiation of disease specific treatment, such as chemotherapy plus or minus therapies for direct
removal of FLCs.
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Background
Immunoglobulin free light chains (FLCs) are by-products
of immunoglobulin synthesis and in normal subjects are
released into the circulation in small quantities [1]. The
FLCs are then rapidly removed by renal clearance [2]. In
patients with multiple myeloma, however, the clonal pro-
liferation of plasma cells can produce FLCs in quantities
thousands of times higher than normal [3]. These mono-
clonal FLCs often result in renal pathologies, most impor-
tantly cast nephropathy [4-6]. Indeed, multiple myeloma
is the haematological malignancy most commonly associ-
ated with acute kidney injury (AKI) [7]. It has been pro-
posed that the combination of multiple myeloma and AKI
should be treated as a medical emergency with prompt
diagnosis and intervention to avoid irreversible renal fail-
ure [8]. However, the standard screening tests for mye-
loma, serum protein electrophoresis (SPE) and urine
Bence Jones protein analysis are not always requested or
reported promptly.
Recently, immunoassays which measure the concentra-
tion of FLCs in serum have been incorporated into haema-
tological screening algorithms for myeloma [9-11]. These
FLC assays are automated and allow same-day analysis
and reporting of results. With these assays, the presence of
monoclonal FLC production is indicated when the ratio
of kappa (κ) to lambda (λ) serum FLCs is outside the ref-
erence range of 0.26–1.65 [12]. The presence of an abnor-
mal FLC ratio, suggestive of monoclonal FLCs production
can occur in the settings of both intact immunoglobulin
multiple myeloma and light chain only multiple mye-
loma. The identification of monoclonal protein produc-
tion is not proof of multiple myeloma, but indicates that
further investigations are required (principally a bone
marrow biopsy and skeletal survey).
For patients presenting with AKI, more rapid identifica-
tion of multiple myeloma may lead to earlier interven-
tions and improved patient outcome. However, there are
no reported evaluations of the diagnostic utility of FLC
assays in this setting. One complicating factor is that
patients with renal impairment can have κ/λ FLC ratios
slightly above the reference range with no other evidence
of monoclonal proteins [13,14]. This reflects a change in
the dynamics of serum FLC clearance in renal failure. In
normal subjects, the clearance of FLC from the serum is
dominated by renal removal of FLCs which is preferential
to the smaller, monomeric, κ molecules. This gives a
shorter serum half-life for κ and a median κ/λ FLC ratio of
approximately 0.6. As the kidneys fail, however, the non-
preferential reticulo-endothial route forms an increasing
proportion of the FLC clearance [15]. This results in a
more similar serum half-life for the two FLCs and the FLC
ratio therefore becomes increasingly influenced by the
underlying production rates, by the plasma cells. There are
approximately twice as many κ producing cells as there
are λ cells [16] and this results in a ratio of total κ to total
λ in the serum of approximately 1.8 [12].
As expected, FLC analysis of sera from 688 patients with
pre-dialysis, chronic kidney disease but no evidence of
monoclonal immunoglobulin production (by serum
immunofixation electrophoresis) demonstrated the
serum κ and λ FLC concentrations increased with decreas-
ing renal function, FLC ranges: 3–251 mg/L and 1–251
mg/L, respectively. The κ/λ FLC ratio increased with each
increasing chronic kidney disease stage, through stages: 1–
5 (population's serum creatinine: 56–875 μmol/L; esti-
mated GFR: 6–128 mL/min/1.73 m2). The median κ/λ
FLC ratio of the population was 1.1 with a 100% range of
0.37–3.1 [17]. This change in the ratio could reduce the
diagnostic utility of FLC analysis in renal impairment. We
propose that modifying the κ/λ reference range to 0.37–
3.1 may improve the diagnostic specificity when investi-
gating patients with renal failure.
The aim of this study was to evaluate serum FLC measure-
ment as a diagnostic tool for detecting monoclonal FLCs
and underlying multiple myeloma, in patients with dialy-
sis-dependent AKI. The sensitivity and specificity of the
published reference range was compared with the pro-
posed renal failure reference range.
Subject and methods
Patients
This study was undertaken in the departments of clinical
immunology and the renal unit, at the University Hospi-
tal Birmingham as part of routine service development
(audit reference: CA4-02015-08) and fully complies with
the Declaration of Helsinki. All data analysis was coded
and anonymised. Sera from patients who presented with
new dialysis-dependent renal failure, to the renal unit at
the University Hospital Birmingham, were screened for
inclusion in a trial assessing the management of severe
renal failure in multiple myeloma (COREC 05/Q2706/
107, South Birmingham Research Ethics Committee), pre-
liminary results of which have been reported previously
[18].
Initiation of dialysis was by the consulting nephrologist
for the following indications: uremia, hyperkalaemia,
metabolic acidosis and fluid overload in the presence of
renal failure, defined as an estimated glomerular filtration
rate of less than 15 mL/min/1.73 m2; calculated using the
MDRD equation [19]. Identification of the renal pathol-
ogy was determined by the nephrologist following stand-
ard diagnostic pathways. Attribution of the cause of renal
failure to multiple myeloma was based on a renal histol-
ogy or in cases where a renal biopsy was contraindicated
when all other potential causes were excluded. The clini-BMC Nephrology 2008, 9:11 http://www.biomedcentral.com/1471-2369/9/11
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cal diagnosis of multiple myeloma was made by a consult-
ant haematologist in accordance with international
diagnostic criteria [20].
Laboratory analysis
Serum samples were stored at -20°C until thawed for the
current study; previous work has demonstrated the stabil-
ity of FLC concentrations in urine samples over many
years [21] and apparent stability in serum samples [12].
Serum protein electrophoresis (SPE) and immunofixation
electrophoresis (IFE) were undertaken using the Sebia
Hydragel 15/30 Protein kit and the Hydragel 4 Immun-
ofixation PE kit on the Hydrasys system (Sebia, Lisses,
France). Serum κ and λ FLC concentrations were meas-
ured by nephelometry, on a Dade-Behring BN™ II Ana-
lyser, using particle-enhanced, high-specificity,
homogeneous immunoassays (Freelite™, The Binding
Site, Birmingham, UK) [22]. FLC results were compared
with the published reference range for the FLC ratio (κ/λ:
0.26–1.65) [12] and the proposed renal failure reference
range (0.37–3.1). All sera were assessed with SPE and FLC
immunoassays; samples with abnormal results were
investigated further by IFE. Urine of patients with sus-
pected multiple myeloma was assessed for monoclonal
FLCs by immunofixation.
Statistical analysis
Data were analysed using SPSS 14.0 for Windows and the
Mann-Whitney U test was used to compare results from
different patient groups. Receiver operating characteristic
(ROC) curve analysis was used to examine the sensitivity
and specificity of utilizing the standard reference range for
the FLC ratio versus the proposed reference range.
Results
The demographics and selected assay results for the
patients are presented in table 1. There were no significant
differences in the demographics of the AKI patients with
and without myeloma. The patients with multiple mye-
loma however, had higher median serum creatinines at
presentation.
Forty-one of the 142 AKI patients had a clinical diagnosis
of multiple myeloma (Figures 1 and 2). All of these 41
patients had abnormal FLC ratios by both the published
reference range and the proposed reference range. The
proposed reference range increased the specificity of the
assay for diagnosis of multiple myeloma (99% versus
93%), with no loss in sensitivity (100%) and thus
increased the area under the ROC curve (0.96 to 0.99; Fig-
ure 3).
Using the published reference range, seven patients had
abnormal FLC ratios but no clinical diagnosis of multiple
myeloma. Of these, two had monoclonal immunoglobu-
lins identified by IFE and five did not; these five had ratios
just outside the reference range, four above (1.79, 1.90,
1.97, 2.69) and one below (0.24). These ratios were mark-
edly different from those of the patients with multiple
myeloma in this population, with median ratios of 313
(range 4.8–26751) and 0.003 (0.05–0.000004), for κ and
λ producing clones respectively. The two patients with
abnormal FLC ratios and monoclonal immunoglobulin
Table 1: Dialysis populations: demographics and haematological data.
Whole population (n-142) Multiple myeloma patients (n-41)
Male – percentages 39% 56%
Ethnicity – percentages
Caucasian 85% 85%
Afro-Caribbean 4% 5%
South-Asian 8% 10%
Other 3% 0%
Median age in years (range) 70 (19–88) 67 (38–84)
Median serum creatinine μmol/L (range) 529 (274–1758) 622 (302–3000)*
Myeloma type – percentages
IgGκ 24%
IgGλ 22%
IgAκ 7%
IgAλ 15%
IgMλ 2%**
Free κ only 10%
Free λ only 19%
κ light chain class (overall) % 41%
*Serum creatinine significantly higher in multiple myeloma patients compared with the dialysis population as a whole, P < 0.02. **One patient with 
known chronic lymphocytic leukaemia, in remission, presented with acute renal failure and biopsy proven cast nephropathy. Investigation identified 
an intact IgM band on immunofixation electrophoresis with an associated λ FLC, bone marrow examination provided a haematological diagnosis of 
IgM myeloma.BMC Nephrology 2008, 9:11 http://www.biomedcentral.com/1471-2369/9/11
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detected by IFE, but without a diagnosis of myeloma, had
FLC ratios of 1.71 and 1.78. These two patients were clas-
sified as having monoclonal gammopathies of undeter-
mined significance (MGUS); their renal diagnoses were
acute tubular necrosis and renovascular disease, respec-
tively. One further patient, with bilateral hydronephrosis,
had an intact immunoglobulin MGUS detected by SPE
and IFE but normal serum FLCs (ratio 0.95). When the
proposed renal reference range for the FLC ratio was used,
there was only one patient with an abnormal ratio (0.24)
who did not have a diagnosis of myeloma.
Seventeen of the 41 multiple myeloma patients did not
have adequate urine samples sent to the laboratory for
analysis. Of the 24 who did, 10 had monoclonal κ FLCs
detected and 13 had monoclonal λ. The remaining patient
did not have monoclonal FLCs detected by urinary
immunofixation, despite 1780 mg/L of κ FLCs measured
in the serum and a renal diagnosis of cast nephropathy.
Renal biopsies were performed in 27 of the 41 patients
with multiple myeloma. Twenty-five of the 27 had cast
nephropathy as the principal diagnosis; of the two other
biopsies, one showed acute interstitial nephritis the other
acute tubular necrosis (ATN). Of the 13 myeloma patients
who did not have a renal biopsy, one had bilateral
hydronephrosis while the other 12 patients did not have
biopsies undertaken because of clinical contraindications,
predominately thrombocytopenia. The 25 myeloma
patients with proven cast nephropathy had higher median
serum concentrations of monoclonal FLCs than the four
patients with other definitive renal diagnoses (the two
with other histological diagnoses, the patient with bilat-
eral hydronephrosis and another with severe sepsis and a
clinical diagnosis of ATN). Median FLC ratios were: 3081
(range 31–26751) and 0.006 (range 0.0000–0.027) ver-
sus 6.7 (range 4.8–8.6) and 0.02 (0.0004–0.05), respec-
tively. Median monoclonal FLC concentrations were:
10,250 mg/L (range 1,030–69,430) versus 1,068 mg/L
Flow diagram of FLC results and myeloma diagnoses Figure 1
Flow diagram of FLC results and myeloma diagnoses. The proposed reference range reduced the number of false pos-
itive results. *false positive defined as patients with abnormal ratio and normal serum immunofixation. MGUS – monoclonal 
gammopathy of undetermined significance.BMC Nephrology 2008, 9:11 http://www.biomedcentral.com/1471-2369/9/11
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(range 28–3,440), respectively. These differences did not
reach significance (P = 0.13, 0.5 and 0.09, respectively).
The renal diagnoses patients with AKI, who were not diag-
nosed with myeloma were: non-diabetic glomerular
nephritis (17.5%), diabetic kidney disease (15.5%), acute
tubular necrosis (9.5%), renal vascular disease (15%),
interstitial nephritis (5%), urinary tract pathologies
(15.5%) and other (17.5%). The median serum polyclo-
nal FLC concentrations for these patients were: κ-60.7 mg/
L (range 8.2–304); λ-56.4 mg/L (range 11.4–370) and the
median serum FLC ratio was 1.0 (range 0.24–2.69).
Discussion
The purpose of this study was to assess serum free light
chain immunoassays as an aid in the diagnosis of multi-
ple myeloma in patients with severe renal failure. All 41
patients who were diagnosed with multiple myeloma
were identified as abnormal using the assays. The assays
indicate the presence of monoclonal FLCs by comparing
the quantitative measurement of κ FLCs with λ FLCs, as a
κ/λ FLC ratio. In patients with monoclonal κ FLC produc-
tion the ratio is increased and in patients with mono-
clonal λ FLC the ratio is decreased. The sensitivity of the
assays in this setting (100%) was not unexpected as previ-
ous studies have reported greater sensitivity for serum ver-
sus urine detection of monoclonal FLC in both myeloma
[3,23] and AL amyloidosis [24,25].
Before serum FLC assays became available, urine analysis
was the preferred method for identifying monoclonal FLC
production in routine haematological screens for multiple
myeloma and other lymphoproliferative disorders. How-
ever, the collection of urine samples, particularly 24 hour
collections, is frequently problematic. In one screening
study, urine samples were lacking for more than half the
population [13] and in our study population urine sam-
ples were only provided for 24 of 41 myeloma patients. In
an analysis of 428 patients with monoclonal FLCs in their
urine, Katzmann et al [25] found that the combination of
serum electrophoresis tests and serum FLC analysis iden-
tified all patients requiring treatment and could, there-
Serum FLC concentrations in patients with dialysis-dependent, acute renal failure Figure 2
Serum FLC concentrations in patients with dialysis-dependent, acute renal failure. The FLC ratio easily distin-
guishes dialysis patients with κ (triangles) and λ (squares) multiple myeloma from patients with no evidence of monoclonal 
gammopathies (diamonds). Published normal control patients (crosses)12 have significantly lower concentrations of polyclonal 
FLCs compared with the dialysis population (both P < 0.001).BMC Nephrology 2008, 9:11 http://www.biomedcentral.com/1471-2369/9/11
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fore, remove the requirement for urine analysis when
screening [25]. Notably, the urine from one of the mye-
loma patients in our study was reported as normal despite
a clearly abnormal serum FLC concentration. This study,
therefore, provides further evidence that serum FLC assays
may have greater utility for identifying monoclonal FLC
production than urine analysis.
The utility of a screening assay in practice however, is a
function of its specificity as well as its sensitivity. In
patients with renal failure, as glomerular filtration
reduces, renal clearance of all FLCs will decrease. This
results in longer serum half-lives and an increase in the κ/
λ FLC ratio. Previous work we have undertaken demon-
strated that in patients with renal failure, with no evidence
of monoclonal proteins, the median FLC ratio was
increased to 1.1 (range 0.37–3.1) from that of the pub-
lished control population of 0.58 (0.26–1.65) [17]. We
hypothesized that extending the reference range for the
FLC ratio, to take into account this influence of renal func-
tion, would increase the specificity of the assay in patients
with dialysis-dependent renal failure. Use of the pub-
lished reference range for the FLC ratio, 0.26–1.65, gave
the assay a specificity of 93% for patients with myeloma.
This improved to 99% with the proposed extended refer-
ence range (0.37–3.1), indicating the new range may have
a practical benefit by reducing the number of false posi-
tives.
Interpretation of FLC ratios between 1.65 and 3.0 is cur-
rently difficult. We would propose checking the patient's
renal function. If normal, a ratio in this range may be
indicative of a monoclonal process and further laboratory
and clinical investigation will be appropriate. If the renal
function is abnormal, a ratio in the range of 1.65–3.0 is
probably a consequence of the renal impairment; how-
ever further investigation of some patients may be appro-
priate, particularly if AL-amyloidosis is suspected.
An interesting observation of this study was that the
patients with cast nephropathy had higher absolute levels
of the monoclonal free light chain type than the myeloma
patients with other renal pathologies. Although this dif-
ference did not reach significance it adds further evidence
to the findings of Bergner et al who demonstrated that uri-
nary FLC concentrations are higher in patients with cast
nephropathy compared with other FLC related renal
pathologies [26].
As with the findings of previous studies, cast nephropathy
was the predominant cause of dialysis-dependent renal
failure in the patients with multiple myeloma who had
biopsies reported (25/27) [4-6]. Historically, myeloma
patients with biopsy proven cast nephropathy have less
than 25% chance of renal recovery [5,27-29] and a signif-
icantly worse overall survival [30]. Early reversal of the
renal failure however, improves patient survival [30,31].
Novel therapies, currently under evaluation, aim to
increase these renal recovery rates and patient survival.
The focus of the new treatments is to rapidly reduce serum
FLC concentrations, by either effective chemotherapy
alone [32,33] or in combination with direct removal of
FLCs by high-cut-off haemodialysis [31]. Success how-
ever, is likely to depend upon early diagnosis and inter-
vention; as animal models have indicated that within one
month of obstruction, by a cast, irreversible damage has
occurred to the nephron [34]. The role of serum FLCs in
management of patients with multiple myeloma and
renal failure may expand beyond that of a diagnostic tool
and management guide to that of an independent indica-
tor of prognosis as eloquently demonstrated by Kyrtsonis
et al in the general myeloma population [35].
Conclusion
The measurement of serum FLCs can be a practical and
highly sensitive aid in the identification of myeloma as
the underlying pathology in patients with severe renal
failure. Using an extended renal failure reference range for
Receiver operating characteristic curve (ROC) analysis of  serum free light chain ratio analysis in patients with dialysis- dependent renal failure Figure 3
Receiver operating characteristic curve (ROC) analy-
sis of serum free light chain ratio analysis in patients 
with dialysis-dependent renal failure. When using an 
abnormal serum FLC ratio as an indication of underlying mul-
tiple myeloma, comparison with the proposed renal refer-
ence range for the FLC ratio increased the area under the 
curve from that of 0.96 using the published reference range 
(green line, CI: 0.93–0.99; P < 0.001) to 0.99 with the new 
range (blue line, CI: 0.98–1.00; P < 0.001). Use of this new 
reference range did not change the sensitivity.BMC Nephrology 2008, 9:11 http://www.biomedcentral.com/1471-2369/9/11
Page 7 of 8
(page number not for citation purposes)
the FLC ratio increased the specificity of the assays. The
diagnostic accuracy of these assays and their rapid labora-
tory turn-around time should aid nephrologists in their
assessment of acute renal failure.
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